Blueroot Health Expands Voluntary Recall of Vital Nutrients Aller-C Dietary Supplement Due to Undeclared Egg, Hazelnut, and Soy
Blueroot Health is expanding its voluntary recall of Vital Nutrients Aller-C dietary supplements to include all product from lot 25E04. The recall affects approximately 100 and 200 capsule bottles with lot numbers 25E04, 25E04-A, and 25E04-B, expiration date 05/27. The products were distributed nationwide from September 2025 through March 2026 and may contain undeclared egg, hazelnut, and soy allergens, posing a risk of serious or life-threatening allergic reactions.
Recombinant Yeast with Sucrose-Inducible Promoter for Target Protein Expression
USPTO published patent application US20260098241A1 assigned to FUJIFILM Corporation covering recombinant yeast strains containing sucrose-inducible promoters for highly expressing target proteins without methanol, along with production methods and kits.
T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems
T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems
Fungal Spore Production Method Using Dual Liquid Medium
The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.
Mammoth Biosciences CRISPR Dystrophin Editing Patent Application
USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.
Recombinant AAV Vectors for Treating Muscular Dystrophy
USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.
EphA2-binding Peptide and Composition Patent Application
The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.
Macrocyclic CFTR Modulators for Cystic Fibrosis
USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.
Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis
USPTO published patent application US20260098059A1 for peptide compositions targeting β-catenin for treatment of endometriosis. The application covers peptides that bind β-catenin and prevent nuclear translocation, modulating the canonical Wnt pathway. Filed October 10, 2025 under Application No. 19355926. Patent rights are not yet granted; applicants seeking to develop similar therapies should review the published claims for freedom-to-operate considerations.
Ovarian Cancer Diagnostic Marker, Urteste S.A
Ovarian Cancer Diagnostic Marker, Urteste S.A
Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin
USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering methods for treating eosinophil-driven inflammation including severe asthma using a composition for mucosal administration comprising detoxified Escherichia coli labile toxin.
LANMODULIN ORTHOLOGS WITH IMPROVED RARE EARTH SEPARATION PERFORMANCE
USPTO published patent application US20260098064A1 for lanmodulin orthologs (proteins) designed to bind rare earth metals with enhanced REE/REE selectivity. The application covers proteins with four EF hand motifs, methods of using the proteins, and devices/kits containing them. The invention has applications in rare earth element separation and processing.
HPV Vaccine Peptide Constructs with Ligand-Inducible Gene Switch Systems
The USPTO published patent application US20260098063A1 titled 'Human Papillomavirus Vaccines and Uses of the Same.' The application covers engineered HPV molecular vaccine constructs incorporating ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as cytokines, in host cells. The application was filed on July 7, 2025, by inventors including Douglas E. Brough and Cheryl G. Bolinger. Patent applications are published for informational purposes and do not grant enforceable rights until issued as a patent after examination.
Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins
USPTO published patent application US20260098062A1 assigned to Sana Biotechnology, Inc. covering lipid particles comprising variant Paramyxovirus attachment glycoproteins with reduced glycosylation and methods for their production and use. The application (originally filed September 21, 2023) covers viral-based particles with modified G/H proteins and their therapeutic applications.
Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression
USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.
Cancer Treatment Patent Using Quinoline Derivative and Antibody
The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.
MPN Treatment Methods with Therapeutic Compounds
USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.
Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification
USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.
Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease
The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.
Atovaquone Patent, Mast Cell Inflammatory Disease Treatment
Atovaquone Patent, Mast Cell Inflammatory Disease Treatment
mRNA, Protein Vaccine Compositions for Influenza
The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.
Ypsomed AG Injection Device with Improved Conveying Element Patent Application
The European Patent Office published patent application EP4159257A1 for an injection device with improved conveying element, filed by Ypsomed AG. The application lists six inventors and covers IPC classifications A61M 5/20, A61M 5/24, and A61M 5/315 relating to injection mechanisms. The application is designated for validation in 28 European member states including Germany, France, the United Kingdom, Italy, and Spain.
Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment
The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.
Injectable Composition For Drug Delivery Using Poly Ortho Ester Polymer
USPTO published patent application US20260096985A1 for an injectable drug delivery composition using poly ortho ester (POE) polymer. The composition includes one or more solvents and therapeutic agents, including a basic therapeutic agent, with the POE polymer having a glass transition temperature between approximately −10°C and 110°C per ASTM E1640-18. Inventors are Vijay Gyanani and Jeffrey Haley, with European Application No. 19348865 filed October 3, 2025.
ALOX15 Inhibitor Patent Application for Respiratory Disorder Treatment
The USPTO published patent application US20260097102A1 on April 9, 2026, disclosing ALOX15 inhibitors for treating respiratory disorders. Inventors Julie Horowitz and Aris Baras filed the application on October 21, 2025 (Application No. 19364245). The patent covers methods of treating respiratory disorders, identifying at-risk subjects, and detecting ALOX15 variant nucleic acids and polypeptides.
RSV Polyanhydride Nanoparticle Vaccine
The USPTO published patent application US20260096999A9 for a respiratory syncytial virus (RSV) vaccine using polyanhydride nanoparticle delivery technology. The application, filed February 17, 2022 by inventors Steven M. Varga and Kevin L. Legge, claims vaccine compositions including RSV F protein in pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles, with optional adjuvant. Patent applications are published to inform the public and allow monitoring of emerging IP positions in the pharmaceutical sector.
Cysteamine for Treatment, Mitigation and Prevention of SARS-CoV-2 Infections
USPTO published patent application US20260097007A1 for cysteamine and derivatives for treating COVID-19 and related viral infections. Inventors are Jess Thoene and Robert Gavin. The application (No. 19415604) was filed December 10, 2025, and published April 9, 2026.
Metalloenzyme Inhibitor Compounds (Patent Application US20260097034A1)
USPTO published patent application US20260097034A1 for metalloenzyme inhibitor compounds. The application was filed on October 2, 2025 (Application No. 19348647) by inventors Steven Sparks, Christopher M. Yates, Sammy R. Shaver, and William J. Hoekstra. The patent covers compounds having metalloenzyme modulating activity and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.
UV/HEV Light Filtering Compounds and Their Use
USPTO published patent application US20260098007A1 for compounds and their use in filtering ultraviolet (UV) and high-energy visible (HEV) light, invented by Micah Nelp and Anthony Young. The compounds may be used in compositions, consumer products, and packaging materials. This patent grant establishes intellectual property rights for the inventors.
Conjugates for Cancer Treatment - Patent Application US20260097117A1
USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.
Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment
USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.
Fluoro Beta-Carboline Compounds, Bone Formation Method
USPTO published patent application US20260097041A1 for fluoro beta-carboline compounds and methods of promoting bone formation. The application (No. 19202018, filed May 8, 2025) covers compounds of Formula I and their use in orthopedic devices, periodontal devices, and treatment of renal disease, diabetes, bone loss, and cancer. Inventors include Debra Ellies, F. Scott Kimball, and Robert N. Young.
Shionogi Fused Ring GLP-1 Receptor Agonist Patent Application
The USPTO published patent application US20260097037A1 by Shionogi & Co., Ltd. on April 9, 2026, covering fused ring compounds as GLP-1 receptor agonists for pharmaceutical use. The application was filed on September 21, 2023, under application number 19112403. The compounds are represented by formulas (I) and (II), with various substituents including phenyl groups and heterocyclic rings.
COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment
The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.
Tetrahydroquinoline Compounds As Antitumor Agents
USPTO published patent application US20260097029A1 for tetrahydroquinoline compounds of Formula (I) and their salts as disruptors of the FANCM/BTR interaction, useful for hampering FANCM localization to telomeres in tumor treatment. The application (No. 19112485) was filed September 22, 2023 by inventors Sandro Cosconati, Stefano Tomassi, Salvatore Di Maro, and Hilda Amelia Pickett. CPC classifications include A61K 31/4709, A61P 35/00, and C07D 215/06.
Bioanalytical Method Validation for Biomarker Concentrations Guidance
FDA's Center for Drug Evaluation and Research issued guidance FDA-2017-D-6821 to help sponsors validate bioanalytical methods used to evaluate biomarker concentrations in drug and biologic development programs. The guidance applies to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs). It addresses method validation for biomarker analysis in both clinical study samples and nonclinical study samples.
HRSA AIDS Drug Assistance Program Data Report Extension Request
The Health Resources and Services Administration (HRSA) is seeking public comment on extending OMB Control No. 0915-0345 for the AIDS Drug Assistance Program (ADAP) Data Report. The comment period closes on May 13, 2026. This is an administrative information collection extension request for an existing data reporting mechanism used to monitor ADAP program activities.
HRSA Extends Funding to University of Utah for Emergency Medical Services for Children Data Center
The Health Resources and Services Administration (HRSA) has issued a Notice extending funding to the University of Utah for the Emergency Medical Services for Children Data Center (EDC). The document, published in the Federal Register on April 13, 2026, is designated as Notice document number 2026-07035, appearing at citation 91 FR 18867.
Determination That BILTRICIDE (Praziquantel) 600mg Tablet Was Not Withdrawn From Sale
The FDA has issued a determination that BILTRICIDE (Praziquantel) oral tablet, 600 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. This determination affects pharmaceutical manufacturers, healthcare providers, and patients who rely on this anti-parasitic medication. The notice confirms the drug remains available on the market and was not subject to removal due to regulatory safety concerns.
SAMHSA Information Collection OMB Review Request
SAMHSA, a division of HHS, has submitted an information collection request to OMB for review under the Paperwork Reduction Act. The notice announces a 30-day public comment period on proposed data collection activities related to substance abuse and mental health services programs. This is a standard administrative action to gather feedback on existing or modified information collection requirements.
Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes
Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes
Methods for Transgenerational Genome Editing in Plants
The USPTO published patent application US20260098272A1 for methods of transgenerational genome editing in plants. The application discloses nucleic acid constructs encoding RNA-guided nucleases under constitutive promoters combined with guide RNAs for editing plant genomes across generations. Inventors include Giane Balser, Lisa Kanizay, Ramanjot Kaur, Thomas Scott Ream, Zarir Vaghchhipawala, and Chenxi Wu. The application was filed on October 6, 2025, under application number 19350752.
Method for Increasing Recombinant Protein Expression
The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.
Multivalent Trident Aptamers for Molecular Recognition
The USPTO published patent application US20260098270A1 by McMaster University on April 9, 2026. The application covers multivalent trident aptamers comprising a branched linker molecule with 2-3 variable arms connected to a root, designed for enhanced affinity and avidity in target molecular recognition. The aptamers have applications in pharmaceutical, diagnostic, and therapeutic fields.
siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment
The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.
Selective Astrocytic MAGL Inactivation for Alzheimer's Disease Treatment
USPTO published patent application US20260098268A1 for compositions and methods treating Alzheimer's disease through selective astrocytic MAGL inactivation via AAV-mediated gene silencing. Inventors: Chu Chen, Jian Zhang. Filed September 29, 2023. The invention targets neuroinflammation reduction by selectively inactivating MAGL in astrocytes rather than globally, minimizing adverse effects from neuronal 2-AG degradation disruption.
Anti-SIRPalpha Antibody for Tumor Treatment
USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.
Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy
Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy
Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases
The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.
IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application
USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.
Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment
USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.
Compositions and Methods for Identification of VHH Antibodies That Bind a Target Antigen
The USPTO published patent application US20260098255A1 for Broad Institute's VHH antibody identification methods. The application covers compositions and methods for identifying VHH antibodies that bind target antigens. The application (No. 19415305) was filed December 10, 2025, and published April 9, 2026.
CRISPR Methods for Treating Microbial Infections - SNIPR Biome
SNIPR Biome ApS filed USPTO patent application US20260098260A1 covering CRISPR-based methods for treating microbial infections including sepsis, septicemia, SIRS, and septic shock. The application also covers controlling microbiologically influenced corrosion and biofouling in industrial or domestic systems using CRISPR technology. Inventors include Morten Sommer, Virginia Martinez, Eric van der Helm, Jakob Krause Haaber, Ana de Santiago Torio, Christian Grøndahl, and Jasper Clube.
Tricyclic Heteroaryl Compounds as Inhibitors of TYK2 and/or JAK1
The USPTO published patent application US20260098044A1 for tricyclic heteroaryl compounds that inhibit TYK2 and/or JAK1 activity. The compounds are directed toward treating skin, respiratory, ophthalmic, and rectal diseases, cancer, and neuroinflammation. Inventors include Stacey Shepard, Onur Atasoylu, Song Mei, and Jun Pan, with application number 19348390 filed October 2, 2025.
GLP-1 Agonist Acid Salt Patent Application
The USPTO published patent application US20260098042A1 for a novel acid salt form of a GLP-1 receptor agonist (OAD2) invented by Haiwen HU, Li FANG, Fan HU, Xinjie ZHOU, and Fenfen CHEN. The compound is classified under CPC C07D 491/056 and may be useful in treating type 2 diabetes and metabolic disorders. The application was filed August 19, 2025, and published April 9, 2026.
Polycyclic Compound for Treatment of Abnormal Cell Proliferation Diseases
USPTO published patent application US20260098043A1 disclosing a polycyclic compound (CLM-L-PTM) or its pharmaceutical salt for treating abnormal cell proliferation diseases. The application names five inventors and covers pharmaceutical compositions suitable for preparing drugs targeting cell proliferation disorders.
Substituted Heterocycle Fused Gamma-Carbolines Synthesis
The USPTO published patent application US20260098040A1 for improved synthesis methods of substituted heterocycle fused gamma-carbolines, filed by inventor Peng Li on April 11, 2025. The application was published April 9, 2026. The document discloses synthesis methods, intermediates, and production processes for these heterocyclic compounds. No regulatory action or compliance obligations are imposed by this publication.
Fused Bicyclic Pyrimidones as WRN Inhibitors
The USPTO published patent application US20260098041A1 assigned to Incyte Corporation, covering tricyclic pyrimidinones as inhibitors of WRN (Werner syndrome helicase). The application names nine inventors and describes pharmaceutical compositions useful in treating diseases or disorders such as cancer or infections. The application was filed on February 26, 2025, under application number 19063574.
GlaxoSmithKline Meningococcus Vaccine Patent Application US20260097107A1
The USPTO published patent application US20260097107A1 for GlaxoSmithKline Biologicals SA covering meningococcal vaccines containing multiple alleles or variants of the fHbp protein to broaden coverage. The application was filed on October 29, 2025, and names inventors Alessia BIOLCHI, Brunella BRUNELLI, Marzia Monica GIULIANI, and Vega MASIGNANI.
HPV VLP Bioconjugates Patent, Inventprise, Inc
Inventprise, Inc. has published patent application US20260097109A1 covering immunogenic compositions and vaccines comprising HPV virus-like particle (VLP) bioconjugates. The application includes L2 protein conjugates and methods for treating or preventing HPV infection. Filed October 7, 2025, and published April 9, 2026.
Biocatalytic Composition Patent for Lung Cancer Treatment
Biocatalytic Composition Patent for Lung Cancer Treatment
Avirulent Live Bacterial Vaccines Cured of Plasmids Containing Antimicrobial Resistance Genes
USPTO published patent application US20260097106A1 for avirulent live bacterial vaccines cured of plasmids containing antimicrobial resistance genes. The application, filed September 19, 2023, covers a vaccine comprising live avirulent bacterial strains free of AMR gene-carrying plasmids, a synthetic curing plasmid, and methods for treating bacterial infections while preventing AMR gene transfer.
MegaNano Biotech Files Vaccine Patent Using Dendritic Cells
The USPTO published patent application US20260097104A1 filed by MegaNano Biotech, Inc. on June 12, 2025, covering antigen sensitized exogenous immature dendritic cells for vaccine formulations. The application discloses methods of using dead antigen sensitized exogenous immature dendritic cells to elicit immune responses and methods of disease treatment and prevention.
Apo-Fluoxetine Recalled Due to Impurities Out of Specification
Health Canada has issued a Type III health product recall for Apo-Fluoxetine 10mg and 20mg capsules by Apotex Inc. due to impurities being out of specification and out of trend. The recall affects retailer-level distribution. Affected lots include VM4608, VM4612 (20mg) and VM4598 (10mg). Patients with affected product should verify their medication and consult healthcare providers before making any changes to their treatment.
Cardinal Health Angiography Pack and Catheterization Packs Recalled
Health Canada has issued a Type I recall for Cardinal Health Angiography Pack and Catheterization Pack products. The recall affects model numbers SCV30COP18, SCV30COPBN, SCV30COPBO, and SAN30LHTHC. The issue stems from Namic Angiographic Rotating Adaptor (RA) Control Syringes included in these products, which may unwind during use and cause disconnection. Healthcare providers should immediately identify and stop using affected products and contact Cardinal Health for replacement or additional information.
QuickVue Dipstick Strep A Test Recalled - False Positive Results
Health Canada issued a Type II medical device recall for the QuickVue Dipstick Strep A Test (catalog 20125) manufactured by Quidel Corporation due to false positive results. Affected lots include 709509, 709487, 709503, 709684, and 233275. False positives may include faint pink lines as well as pink-to-red test lines. Healthcare providers using these tests should stop using affected lots and contact the manufacturer.
Stryker InZone Detachment System Type II Recall - Battery Drain
Health Canada issued a Type II recall for Stryker Neurovascular's InZone Detachment System. Certain device lots may experience premature battery drain, causing devices to fail to power on, display faint indicators, or be unable to detach coils as intended. Healthcare providers should contact Stryker Neurovascular at 47900 Bayside Parkway, Fremont, CA 94538 to verify affected lot numbers and obtain additional information.